Skip to main content

Table 1 Hospital mortality risk factors (number (%) or median (IQR))

From: Candidemia in critically ill immunocompromised patients: report of a retrospective multicenter cohort study

Clinical features Total
N = 121
Dead
N = 73
Alive
N = 48
p value
Female gender 47 (39%) 24 (33%) 23 (48%) 0.13
Age 60 (49–66) 60 (49–65) 61 (52–68) 0.3
Median year of ICU admission (IQR) 2013 (2010–2015) 2013 (2010–2016) 2013 (2010–2015) 0.86
Underlying immunosuppression
 Solid tumors 36 (30%) 19 (26%) 17 (35%) 0.31
 Hematological malignancy 81 (67%) 52 (71%) 29 (60%) 0.24
 Allogenic SCT 8 (7%) 7 (10%) 1 (2%) 0.14
 Acute myeloid leukemia 17 (14%) 10 (14%) 7 (15%) 1
 Acute lymphoid leukemia 9 (7%) 7 (10%) 2 (4%) 0.32
 Lymphoma 45 (37%) 29 (40%) 16 (33%) 0.56
 Myelodysplasia 6 (5%) 4 (5.5%) 2 (4%) 1
 Autoimmune disease 13 (11%) 7 (10%) 6 (12.5%) 0.77
 HIV infection 19 (16%) 11 (15%) 8 (17%) 0.80
 Neutropenia 58 (49%) 37 (51%) 21 (46%) 0.71
ICU features
 SOFA score 10 (6–15) 12 (8–16) 8 (5–14) 0.011
 Surgical patient 25 (21%) 15 (20%) 10 (21%) 1
 Renal replacement therapy 71 (61%) 50 (68.5%) 22 (46%) 0.005
 Invasive mechanical ventilation 91 (75%) 61 (85%) 31 (65%) 0.015
 Vasopressors 66 (54.5%) 45 (62%) 21 (44%) 0.06
Candidemia features
 Antifungal prophylaxis 20 (17%) 16 (22%) 4 (8%) 0.08
 ICU acquired candidemia 70 (58%) 44 (63%) 26 (54%) 0.5
 Candida albicans 65 (54%) 39 (53%) 26 (54%) 1
 Candida glabrata 23 (19%) 13 (18%) 10 (21%) 0.81
 Candida tropicalis 13 (11%) 9 (12%) 4 (8%) 0.56
 Candida krusei 9 (7%) 7 (10%) 2 (4%) 0.32
 Candida parapsilosis 9 (7%) 5 (7%) 4 (8%) 0.74
 Fluconazole susceptibility 61 (70%) 35 (71%) 27 (69%) 1
 Echinocandins susceptibility 73 (92%) 39 (89%) 34 (97%) 0.22
 Adequacy of first AF therapy 78 (90%) 43 (86%) 36 (94%) 0.29
 CVC removed 103 (97%) 61 (98%) 42 (95.5%) 0.57
 Days to first AF therapy (IQR) 3 (1–3) 3 (1–3) 3 (1–3) 0.45
 Preemptive antifungal therapy 27 (22%) 16 (22%) 11 (23%) 1.00
  1. Adequacy is based on antifungal susceptibility of involved Candida based on MIC
  2. ICU intensive care unit, IQR interquartile range, SCT stem cell transplantation, AF antifungal therapy, CVC central venous catheter